Pieris Pharmaceuticals Inc (NASDAQ:PIRS) Receives Average Rating of “Buy” from Brokerages
Pieris Pharmaceuticals Inc (NASDAQ:PIRS) has been assigned an average recommendation of “Buy” from the six ratings firms that are presently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, two have given a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $6.00.
PIRS has been the topic of several research analyst reports. Zacks Investment Research cut shares of Pieris Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, July 24th. Cowen reissued a “buy” rating on shares of Pieris Pharmaceuticals in a research report on Monday, May 13th. Robe ...